Nasdaq stocks posting largest percentage decreases
AP - Fri May 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Vanda Pharmaceuticals Down 25.2% Since SmarTrend Downtrend Call (VNDA)
Comtex SmarTrend(R) - Fri May 09, 9:16AM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on April 11th, 2014 at $13.69. In approximately 4 weeks, Vanda Pharmaceuticals has returned 25.17% as of today's recent price of $10.24.
Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin , Jazz Pharmaceuticals and Vanda Pharmaceuticals . Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...
Vanda Pharmaceuticals Reports First Quarter 2014 Results
PR Newswire - Thu May 08, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2014.
Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
Today's Dead Cat Bounce Stock: Vanda Pharmaceuticals (VNDA)
at The Street - Mon Apr 28, 9:15AM CDT
Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Vanda Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 8, 2014
PR Newswire - Thu Apr 24, 4:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the first quarter of 2014 on Thursday, May 8, 2014, before the market opens.
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
Vanda Pharmaceuticals Announces Availability of HETLIOZ(TM) (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)
PR Newswire - Wed Apr 09, 6:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.
Vanda Pharmaceuticals Shares Up 22.5% Since SmarTrend's Buy Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 08, 11:10AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 22.53% as of today's recent price of $15.31.
Vanda Pharmaceuticals Has Returned 33.8% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 01, 9:43AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 33.81% as of today's recent price of $16.72.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
41.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Tue Mar 25, 9:18AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 41.74% as of today's recent price of $17.71.
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 3:25PM CDT
You might be compelled to think that territorial tensions between Russia and Ukraine and generally mixed economic data might push the market lower, but you'd be sorely mistaken. In fact, new highs are outpacing new lows by close to a 10-to-1 margin...
Breakfast Round-up - 52-Weeks High Reset: NextEra Energy, Silver Standard Resources, Wisconsin Energy, and Vanda Pharma
PR Newswire - Tue Mar 18, 8:39AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1,858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include NextEra Energy Inc. (NYSE:NEE), Silver Standard Resources Inc. (NASDAQ:SSRI), Wisconsin Energy Corporation (NYSE MKT: WEC), and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Free research on these four companies can be accessed at: